Finasteride and erectile dysfunction are often discussed together because the drug alters androgen metabolism, and sexual function depends on a coordinated interaction between hormones, vascular signaling, neurologic arousal, and psychological context. Finasteride is widely prescribed as a 1 mg daily tablet for male androgenetic alopecia and as a 5 mg dose for benign prostatic hyperplasia. Most men who use it do not develop clinically significant erectile dysfunction, but controlled trials, observational studies, and pharmacovigilance data suggest that a subset of men report sexual adverse effects, including reduced libido, ejaculatory changes, and difficulty achieving or maintaining erections.
The clinical question is not whether every symptom after finasteride is caused by finasteride. It is whether the medication can contribute to sexual dysfunction in some men, how large that risk appears to be, why some reports persist after discontinuation, and how physicians should evaluate men who develop symptoms while taking a 5-alpha-reductase inhibitor.
Finasteride and Erectile Dysfunction: The Hormonal Context
Finasteride inhibits type II 5-alpha-reductase, the enzyme that converts testosterone into dihydrotestosterone (DHT). DHT has a central role in prostate tissue and hair follicle biology, which explains why finasteride can reduce prostate volume and slow androgen-driven hair loss. The same biology also creates a plausible pathway for sexual adverse effects, because androgen signaling contributes to libido, genital tissue physiology, nitric oxide synthase activity, and central sexual motivation.
That does not mean DHT is the sole driver of erections. Penile erection is primarily a vascular-neurologic event. Sexual stimulation triggers nitric oxide release from nerves and endothelial cells in penile tissue. Nitric oxide increases cyclic guanosine monophosphate (cGMP), smooth muscle relaxes, arterial inflow rises, and venous outflow is mechanically restricted. Testosterone status, endothelial function, autonomic tone, sleep, mood, medications, alcohol intake, metabolic health, and relationship factors can all influence this sequence.
For that reason, a man who develops erectile dysfunction while taking finasteride should not be evaluated through a single-cause lens. The timing matters, but so do blood pressure, lipids, glucose control, sleep quality, depressive symptoms, pornography or performance anxiety patterns, pelvic pain, other medications, and baseline sexual function before starting treatment. Finasteride may be part of the history; it should not replace a full medical assessment.
What Randomized Trials and Meta-Analyses Suggest
Randomized trial evidence generally indicates that sexual adverse effects occur in a minority of men taking finasteride, and that the absolute event rate is low. The signal is not zero, however. A systematic review of finasteride for androgenetic alopecia found moderate-quality evidence that oral finasteride increased the risk of erectile dysfunction compared with placebo, with a reported relative risk of 2.22, although the number needed to harm was estimated at approximately 82 men treated. That means the relative increase can look clinically meaningful while the absolute risk for an individual patient remains modest.
A later meta-analysis of 15 randomized, double-blind, placebo-controlled trials involving 4,495 men treated for androgenetic alopecia found that oral 5-alpha-reductase inhibitors were associated with a 1.57-fold risk of adverse sexual effects. In subgroup analysis, finasteride 1 mg carried a relative risk of 1.66 for adverse sexual effects compared with placebo. The authors also noted signals for decreased libido and erectile dysfunction, while emphasizing that dutasteride data were more limited.
These data support a balanced interpretation. Finasteride appears well tolerated for most men, but clinicians should counsel patients that sexual side effects can occur. The evidence does not justify framing erectile dysfunction as inevitable, nor does it justify dismissing symptoms as unrelated simply because the average trial participant did not experience them.
Why Observational Studies Complicate the Picture
Large observational studies add a different perspective because they capture real-world prescribing rather than highly selected trial populations. A population-based analysis using the UK Clinical Practice Research Datalink evaluated men using 5-alpha-reductase inhibitors for benign prostatic hyperplasia or alopecia. In the alopecia cohort, finasteride 1 mg was not associated with a statistically significant increase in incident erectile dysfunction compared with unexposed men with alopecia. In the benign prostatic hyperplasia cohort, erectile dysfunction risk appeared more closely related to the duration of the underlying prostate condition than to 5-alpha-reductase inhibitor exposure itself.
That finding is important because it shows how confounding can distort medication-risk discussions. Men taking finasteride for prostate enlargement may already have age-related vascular disease, urinary symptoms, sleep disruption, metabolic syndrome, or medication exposures that independently raise the likelihood of erectile dysfunction. Younger men taking finasteride for hair loss may have fewer vascular risk factors, but they may also be more likely to monitor sexual symptoms closely after reading about adverse effects online.
The nocebo effect is clinically real: expectation of harm can increase symptom reporting. At the same time, nocebo does not prove that every reported symptom is psychological. In practice, physicians should avoid two extremes. They should not attribute every erection change to finasteride without evaluation, and they should not dismiss a temporal relationship that is meaningful to the patient. A careful medication timeline, symptom inventory, and risk-factor assessment are more useful than certainty unsupported by evidence.
Persistent Symptoms and the Limits of Current Evidence
The most controversial topic is persistence after discontinuation, sometimes discussed under the label post-finasteride syndrome. Persistent sexual symptoms have been reported in case series, interviews, and retrospective analyses, but the strength of causal evidence is weaker than for short-term adverse effects during therapy.
One retrospective cohort study of electronic medical records reported persistent erectile dysfunction in 1.4% of men exposed to finasteride or dutasteride, defined as erectile dysfunction lasting at least 90 days after discontinuation with contemporaneous phosphodiesterase-5 inhibitor treatment. Among younger men exposed to low-dose finasteride, 0.8% met the study definition. Longer exposure duration was associated with higher risk in that analysis. These findings are clinically notable, but they do not settle causality because retrospective designs can be affected by documentation patterns, selection bias, unmeasured confounding, and the difficulty of reconstructing baseline sexual function.
Other reviews have emphasized that reports of persistent dysfunction are concerning but limited by bias, while older controlled trials generally did not document persistent irreversible sexual dysfunction as a common outcome. The correct clinical stance is therefore cautious rather than dogmatic. Persistent symptoms appear uncommon, but they deserve medical evaluation, especially when they affect quality of life, mood, relationships, or adherence to other treatments.
Men should seek care promptly if erectile dysfunction is sudden, accompanied by loss of libido or mood changes, persists after stopping a medication, or occurs alongside chest pain, exercise intolerance, new urinary symptoms, testicular pain, neurologic symptoms, or signs of low testosterone. Erectile dysfunction can be an early marker of cardiometabolic disease, and medication timing should not prevent a broader health workup.
Clinical Evaluation and Treatment Considerations
Evaluation begins with a structured history. A clinician will usually ask when finasteride was started, whether the dose changed, when symptoms began, whether libido, orgasm, ejaculation, morning erections, or penile rigidity changed, and whether symptoms occur in all sexual contexts. The distinction between reduced desire and impaired erection is important because low libido points more strongly toward hormonal, mood, medication, or relationship factors, while situational erection difficulty may suggest performance anxiety or context-specific arousal disruption.
Laboratory testing may include morning total testosterone, free testosterone when appropriate, luteinizing hormone, prolactin, thyroid-stimulating hormone, fasting glucose or hemoglobin A1c, lipids, and other studies based on history. Blood pressure, waist circumference, alcohol intake, sleep apnea risk, depression screening, and medication review are often as important as hormone testing.
Management depends on severity, goals, and risk tolerance. Some men and their physicians choose watchful waiting if symptoms are mild and hair-loss benefit is important. Others consider stopping finasteride, switching to topical strategies, changing dose, or using non-hormonal hair-loss approaches. If erectile dysfunction persists, evidence-based treatment may include lifestyle intervention, psychosexual support when anxiety or relationship dynamics are involved, and prescription erectile dysfunction therapy when medically appropriate.
Phosphodiesterase-5 inhibitors can improve penile blood-flow signaling by preserving cGMP activity, but they require medical screening, especially for men using nitrates, alpha blockers, or certain cardiovascular medications. Central arousal, nitric oxide signaling, endothelial health, and hormonal context can all influence response. For men whose symptoms include both arousal difficulty and vascular erection difficulty, a physician may consider different treatment strategies than for men with isolated performance anxiety or isolated low testosterone.
Conclusion
The evidence on finasteride and erectile dysfunction is nuanced. Randomized trials and meta-analyses suggest a small but measurable increase in sexual adverse effects for some men, while large observational data do not consistently show a major increase in incident erectile dysfunction after accounting for indication and baseline risk. Persistent symptoms have been reported and should be taken seriously, but the causal evidence remains less definitive than the evidence for short-term sexual side effects during treatment. Men who notice erectile changes while using finasteride should discuss the timeline with a clinician, avoid abrupt assumptions, and receive a complete evaluation for vascular, hormonal, neurologic, medication-related, and psychological contributors.
If you're exploring clinically-formulated options, OnyxMD offers physician-supervised treatment plans, including VAST, starting with a free online assessment at questionnaire.getonyxmd.com. You can also read more evidence-focused men's health articles in the OnyxMD blog.
These statements have not been evaluated by the FDA. This content is for informational purposes only and does not constitute medical advice.
References
Mella JM, Perret MC, Manzotti M, Catalano HN, Guyatt G. Efficacy and safety of finasteride therapy for androgenetic alopecia: a systematic review. Archives of Dermatology. 2010;146(10):1141-1150. doi:10.1001/archdermatol.2010.256
Lee S, Lee YB, Choe SJ, Lee WS. Adverse sexual effects of treatment with finasteride or dutasteride for male androgenetic alopecia: a systematic review and meta-analysis. Acta Dermato-Venereologica. 2019;99(1):12-17. doi:10.2340/00015555-3035
Hagberg KW, Divan H, Persson R, Nickel JC, Jick SS. Risk of erectile dysfunction associated with use of 5-alpha reductase inhibitors for benign prostatic hyperplasia or alopecia: population based studies using the Clinical Practice Research Datalink. BMJ. 2016;354:i4823. doi:10.1136/bmj.i4823
Kiguradze T, Temps WH, Yarnold PR, Cashy J, Brannigan RE, Nardone B, Micali G, West DP, Belknap SM. Persistent erectile dysfunction in men exposed to the 5-alpha reductase inhibitors, finasteride, or dutasteride. PeerJ. 2017;5:e3020. doi:10.7717/peerj.3020
Medical Disclaimer: The information provided on this website is for educational and informational purposes only and is not intended as medical advice. OnyxMD services should not be used to diagnose, treat, cure, or prevent any disease or medical condition. Always consult with a qualified healthcare provider before beginning any supplement regimen or health program.
FDA Disclaimer: These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
Individual Results: Results may vary. The experiences and testimonials presented on this website are individual results that may not be typical. Your experience may be different.
Telehealth Services: OnyxMD provides telehealth services in 47 states (excluding AK, MS, NJ) through licensed healthcare providers via our partner Beluga Health, P.A. Services are subject to clinical evaluation and may not be appropriate for all individuals. Prescriptions fulfilled by Strive Pharmacy LLC (License #99-9817) and EPIQ SCRIPTS LLC.